AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29500207 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher body mass index (BMI)
Number of subjects: 1206
Study 29500572 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (CIP) 750 mg prophylaxis
Number of subjects: 207
Study 29500837 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft tissue grafting or implant surgery
Number of subjects: 213
Study 29500837 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedation during surgery
Number of subjects: 213
Study 29500837 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 213
Study 29500837 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain pill use
Number of subjects: 213
Study 29500837 — intervention group
Group type: EXPERIMENTAL
Intervention: Nervousness prior to surgery
Number of subjects: 213
Study 29500837 — intervention group
Group type: EXPERIMENTAL
Intervention: Actual pain experienced
Number of subjects: 213
Study 29501599 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep healing (combination of transmural and mucosal healing)
Number of subjects: 151
Study 29501599 — intervention group
Group type: EXPERIMENTAL
Intervention: Transmural healing with mucosal inflammation
Number of subjects: 151
Study 29501599 — intervention group
Group type: EXPERIMENTAL
Intervention: Mucosal and transmural inflammation
Number of subjects: 151
Study 29501599 — intervention group
Group type: EXPERIMENTAL
Intervention: Fecal calprotectin
Number of subjects: 151
Study 29501599 — intervention group
Group type: EXPERIMENTAL
Intervention: C-reactive protein
Number of subjects: 151
Study 29501741 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-wide, multi-level intervention including comic books, multi-generational nutrition and PA classes, teacher-led PA breaks, media literacy education, family nights, a farmer's market, and a community PA event (ciclovia) over 2 years.
Number of subjects: 900
Study 29501741 — intervention group
Group type: COMPARATOR
Intervention: Two newsletters sent to the comparison community.
Number of subjects: 900
Study 29501806 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 1767
Study 29501806 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 1767
Study 29501806 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 1767
Study 29502085 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery calcification (CAC) >0 AU in NSCP patients
Number of subjects: 229
Study 29502085 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac events in NSCP patients
Number of subjects: 229
Study 29502085 — intervention group
Group type: COMPARATOR
Intervention: Cardiac events in background population
Number of subjects: 229
Study 29502085 — intervention group
Group type: EXPERIMENTAL
Intervention: CAC >100 AU in NSCP patients
Number of subjects: 229
Study 29502085 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequency of cardiac endpoints
Number of subjects: 229
Study 29502304 — intervention group
Group type: EXPERIMENTAL
Intervention: Accu-Chek (System A)
Number of subjects: 0
Study 29502304 — intervention group
Group type: EXPERIMENTAL
Intervention: System B
Number of subjects: 0
Study 29502304 — intervention group
Group type: EXPERIMENTAL
Intervention: System C
Number of subjects: 0
Study 29502304 — intervention group
Group type: EXPERIMENTAL
Intervention: System D
Number of subjects: 0
Study 29502304 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin dosing errors (lay-users)
Number of subjects: 0
Study 29502304 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin dosing errors (study personnel)
Number of subjects: 0
Study 29502304 — intervention group
Group type: EXPERIMENTAL
Intervention: All SMBG systems
Number of subjects: 0
Study 29502530 — intervention group
Group type: EXPERIMENTAL
Intervention: HIRREM® intervention
Number of subjects: 18
Study 29502594 — intervention group
Group type: EXPERIMENTAL
Intervention: VABEM (vindesine, doxorubicin, carmustine, etoposide, and methylprednisolone)
Number of subjects: 51
Study 29502924 — intervention group
Group type: EXPERIMENTAL
Intervention: Abbott FreeStyle Libre
Number of subjects: 0
Study 29502924 — intervention group
Group type: COMPARATOR
Intervention: Dexcom G5 mobile
Number of subjects: 0
Study 29503006 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous axillary artery access (pAxA) using two Perclose ProGlide devices
Number of subjects: 34
Study 29503006 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up of patients who underwent pAxA
Number of subjects: 34
Study 29503006 — intervention group
Group type: EXPERIMENTAL
Intervention: Anatomic characteristics of the AxA
Number of subjects: 34
Study 29504053 — intervention group
Group type: EXPERIMENTAL
Intervention: Duodenal-Jejunal Bypass Liner (DJBL)
Number of subjects: 77
Study 29504262 — intervention group
Group type: EXPERIMENTAL
Intervention: High Fat/High Sugar (HF/HSS) intake
Number of subjects: 214
Study 29504262 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy Density (EnDen)
Number of subjects: 214
Study 29504483 — intervention group
Group type: EXPERIMENTAL
Intervention: sTMS (four pulses twice daily)
Number of subjects: 263
Study 29504483 — intervention group
Group type: EXPERIMENTAL
Intervention: sTMS
Number of subjects: 263
Study 29505098 — intervention group
Group type: EXPERIMENTAL
Intervention: VEMOFIT (emotion-focused educational programme)
Number of subjects: 124
Study 29505098 — intervention group
Group type: COMPARATOR
Intervention: Attention control programme (active listening, social support)
Number of subjects: 124
Study 29505137 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients' perception of malnutrition
Number of subjects: 2197
Study 29505137 — intervention group
Group type: EXPERIMENTAL
Intervention: Relatives' perception of malnutrition
Number of subjects: 2197
Study 29505137 — intervention group
Group type: EXPERIMENTAL
Intervention: Physicians' perception of malnutrition
Number of subjects: 2197
Study 29505137 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall prevalence of malnutrition
Number of subjects: 2197
Study 29505450 — intervention group
Group type: EXPERIMENTAL
Intervention: Customized device for measuring VO2
Number of subjects: 14
Study 29505450 — intervention group
Group type: EXPERIMENTAL
Intervention: Customized device for measuring VCO2
Number of subjects: 14
Study 29505450 — intervention group
Group type: EXPERIMENTAL
Intervention: Customized device for measuring EE
Number of subjects: 14
Study 29505450 — intervention group
Group type: EXPERIMENTAL
Intervention: Customized device
Number of subjects: 14
Study 29505600 — intervention group
Group type: EXPERIMENTAL
Intervention: A20 upregulation during treated HIV disease
Number of subjects: 0
Study 29505699 — intervention group
Group type: EXPERIMENTAL
Intervention: IMADETECT™ diagnostic test for patient inclusion and personalized target selection
Number of subjects: 0
Study 29505795 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducational intervention (one face-to-face session and two phone sessions delivered by a nurse)
Number of subjects: 102
Study 29505795 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 102
Study 29506157 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoglycemic intravenous glucose infusion (IIGI)
Number of subjects: 4
Study 29506157 — intervention group
Group type: COMPARATOR
Intervention: Oral glucose tolerance test (OGTT)
Number of subjects: 4
Study 29506392 — intervention group
Group type: EXPERIMENTAL
Intervention: Ensartinib (X-396)
Number of subjects: 0
Study 29506392 — intervention group
Group type: COMPARATOR
Intervention: Crizotinib
Number of subjects: 0
Study 29506478 — intervention group
Group type: EXPERIMENTAL
Intervention: S-1 and oxaliplatin (SOX)
Number of subjects: 36
Study 29506503 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum klotho levels
Number of subjects: 2101
Study 29506503 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 2101
Study 29506523 — intervention group
Group type: EXPERIMENTAL
Intervention: RAAS inhibition treatment
Number of subjects: 94
Study 29506579 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flow nasal oxygen (HFNO) therapy
Number of subjects: 0
Study 29506579 — intervention group
Group type: COMPARATOR
Intervention: Standard oxygen therapy
Number of subjects: 0
Study 29506984 — intervention group
Group type: EXPERIMENTAL
Intervention: LDL-C <70 mg/dL
Number of subjects: 2518
Study 29506984 — intervention group
Group type: EXPERIMENTAL
Intervention: LDL-C <100 mg/dL
Number of subjects: 2518
Study 29506984 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-HDL-C targets
Number of subjects: 2518
Study 29506984 — intervention group
Group type: EXPERIMENTAL
Intervention: ApoB targets
Number of subjects: 2518
Study 29506988 — intervention group
Group type: EXPERIMENTAL
Intervention: Duligotuzumab (MEHD7945A)
Number of subjects: 0
Study 29506988 — intervention group
Group type: COMPARATOR
Intervention: Cetuximab in combination with FOLFIRI
Number of subjects: 0
Study 29507062 — intervention group
Group type: EXPERIMENTAL
Intervention: Piperacillin 4 g every 8 h
Number of subjects: 22
Study 29507062 — intervention group
Group type: EXPERIMENTAL
Intervention: Piperacillin
Number of subjects: 22
Study 29507070 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ganciclovir therapy; specific dosage and duration not mentioned.
Number of subjects: 0
Study 29507077 — intervention group
Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin with cyclophosphamide, doxorubicin, and prednisone (BV+CHP; 6 cycles, then up to 10 cycles of brentuximab vedotin monotherapy)
Number of subjects: 26
Study 29507099 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-hour urinary sodium excretion (118.7 mmol)
Number of subjects: 4680
Study 29507099 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium intake
Number of subjects: 4680
Study 29507099 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary sodium
Number of subjects: 4680
Study 29507706 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized supervised exercise program (DAPS)
Number of subjects: 36
Study 29507706 — intervention group
Group type: COMPARATOR
Intervention: Standard intervention (gym-membership with limited instructions and general dietary advice)
Number of subjects: 36
Study 29507732 — intervention group
Group type: EXPERIMENTAL
Intervention: Occupational multicomponent rehabilitation including physical exercise and cognitive behavioral therapy (ACT) for either 8 or 17 full days.
Number of subjects: 30
Study 29507732 — intervention group
Group type: EXPERIMENTAL
Intervention: Occupational multicomponent rehabilitation including physical exercise and ACT
Number of subjects: 30
Study 29507971 — intervention group
Group type: EXPERIMENTAL
Intervention: Grazoprevir (GZR), 100 mg, and Elbasvir (EBR), 50 mg, immediately before transplantation; continued GZR-EBR for 12 weeks after transplantation for genotype 1 infection, and added Sofosbuvir, 400 mg, for genotype 2 or 3 infection for 12 weeks of triple therapy.
Number of subjects: 10
Study 29508095 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramucirumab 8 mg/kg every 2 weeks
Number of subjects: 36
Study 29508268 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics (Saccharomyces boulardii, Bifidobacterium lactis, Lactobacillus acidophilus, Lactobacillus plantarum)
Number of subjects: 26
Study 29508268 — intervention group
Group type: COMPARATOR
Intervention: Control group (IBS without SIBO)
Number of subjects: 26
Study 29509034 — intervention group
Group type: EXPERIMENTAL
Intervention: Adipose graft transposition procedure (AGTP)
Number of subjects: 0
Study 29509034 — intervention group
Group type: EXPERIMENTAL
Intervention: AGTP
Number of subjects: 0
Study 29509546 — intervention group
Group type: EXPERIMENTAL
Intervention: PARP-1 PET imaging agent
Number of subjects: 0
Study 29509764 — intervention group
Group type: EXPERIMENTAL
Intervention: High multimorbidity class (concomitant heart failure, peripheral vascular disease, and hypertension)
Number of subjects: 693388
Study 29509764 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium multimorbidity class (peripheral vascular disease and hypertension)
Number of subjects: 693388
Study 29509764 — intervention group
Group type: COMPARATOR
Intervention: Low multimorbidity class
Number of subjects: 693388
Study 29509764 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacological therapies (aspirin, β-blockers, statins)
Number of subjects: 693388
Study 29509992 — intervention group
Group type: EXPERIMENTAL
Intervention: Eplerenone (25 mg daily for 1 week followed by 50 mg daily for 23 weeks)
Number of subjects: 5
Study 29510707 — intervention group
Group type: EXPERIMENTAL
Intervention: Watching television
Number of subjects: 173
Study 29510707 — intervention group
Group type: EXPERIMENTAL
Intervention: Using a computer
Number of subjects: 173
Study 29510707 — intervention group
Group type: EXPERIMENTAL
Intervention: Reading
Number of subjects: 173
Study 29510707 — intervention group
Group type: EXPERIMENTAL
Intervention: Socializing
Number of subjects: 173
Study 29510709 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 different non-wear criteria (≥ 10, 20, 30, 45, 60, and 90 min of consecutive zero counts without interruptions; ≥60 and 90 min with allowance for 1 and 2 min interruptions)
Number of subjects: 891
Study 29510709 — intervention group
Group type: EXPERIMENTAL
Intervention: Log of non-wear periods
Number of subjects: 891
Study 29510709 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-wear criteria
Number of subjects: 891
Study 29510709 — intervention group
Group type: EXPERIMENTAL
Intervention: Suggested non-wear criterion
Number of subjects: 891
Study 29510735 — intervention group
Group type: EXPERIMENTAL
Intervention: Single 2-h pain catastrophizing class
Number of subjects: 231
Study 29510735 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain-CBT (eight weekly 2-h group sessions with home exercises and readings)
Number of subjects: 231
Study 29510735 — intervention group
Group type: COMPARATOR
Intervention: Single 2-h back pain health education class
Number of subjects: 231
Study 29510739 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab therapy
Number of subjects: 9
Study 29510755 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole exome sequencing (WES) methodology using Illumina HiSEQ 2500
Number of subjects: 3
Study 29510755 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole exome sequencing (WES) methodology
Number of subjects: 3
Study 29510972 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapted Wii Fit Balance Board
Number of subjects: 0
Study 29510972 — intervention group
Group type: COMPARATOR
Intervention: OTS Wii Fit Balance Board
Number of subjects: 0
Study 29510971 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile app for monitoring symptoms and patient performance during radiotherapy
Number of subjects: 50
Study 29511004 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimorbidity assessed with the adjusted morbidity grouper
Number of subjects: 264830
Study 29511004 — intervention group
Group type: EXPERIMENTAL
Intervention: High healthcare costs to year ratio
Number of subjects: 264830
Study 29511014 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative delirium assessed using the Confusion Assessment Method on postoperative days 1, 2, 3, and day of discharge.
Number of subjects: 0
Study 29511014 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative assessments including hospital outcomes, pain at rest, knee and hip function, health-related quality of life, and Postoperative Morbidity Survey-defined morbidity.
Number of subjects: 0
Study 29511132 — intervention group
Group type: EXPERIMENTAL
Intervention: OPB-111077, 250 mg QD (maximum tolerated dose)
Number of subjects: 145
Study 29511132 — intervention group
Group type: EXPERIMENTAL
Intervention: OPB-111077, 250 mg QD
Number of subjects: 145
Study 29511383 — intervention group
Group type: EXPERIMENTAL
Intervention: Levodopa-carbidopa intestinal gel (LCIG)
Number of subjects: 28
Study 29511906 — intervention group
Group type: EXPERIMENTAL
Intervention: SCP care
Number of subjects: 395
Study 29511906 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 395
Study 29512061 — intervention group
Group type: EXPERIMENTAL
Intervention: Avelumab (immunotherapy)
Number of subjects: 19
Study 29512061 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy and radiotherapy
Number of subjects: 19
Study 29512219 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct-acting antiviral agents
Number of subjects: 0
Study 29513219 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 29514175 — intervention group
Group type: EXPERIMENTAL
Intervention: Low isoniazid and rifampicin concentrations
Number of subjects: 268
Study 29514175 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest quartile for area under the rifampicin and isoniazid concentration-time curves
Number of subjects: 268
Study 29514175 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampicin and isoniazid concentrations below the thresholds and weight <55 kg
Number of subjects: 268
Study 29514175 — intervention group
Group type: EXPERIMENTAL
Intervention: Low antituberculosis drug concentrations
Number of subjects: 268
Study 29514256 — intervention group
Group type: EXPERIMENTAL
Intervention: Ombrabulin (15.5 mg/m2), Docetaxel (60 mg/m2), Cisplatin (75 mg/m2)
Number of subjects: 11
Study 29514256 — intervention group
Group type: EXPERIMENTAL
Intervention: Ombrabulin (15.5 mg/m2), Docetaxel (60 mg/m2), Cisplatin (75 mg/m2) with prophylactic G-CSF
Number of subjects: 11
Study 29514256 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel (60 mg/m2) monotherapy
Number of subjects: 11
Study 29514568 — intervention group
Group type: EXPERIMENTAL
Intervention: DPP Group Lifestyle Balance (GLB) - immediate intervention
Number of subjects: 134
Study 29514568 — intervention group
Group type: COMPARATOR
Intervention: Delayed intervention (control group)
Number of subjects: 134
Study 29514611 — intervention group
Group type: EXPERIMENTAL
Intervention: TECNIS® ZKB00 (+2.75 D) in dominant eye and TECNIS® ZLB00 (+3.25 D) in non-dominant eye
Number of subjects: 20
Study 29514611 — intervention group
Group type: EXPERIMENTAL
Intervention: TECNIS® ZKB00 (+2.75 D) and TECNIS® ZLB00 (+3.25 D)
Number of subjects: 20
Study 29514648 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking (intervention group)
Number of subjects: 0
Study 29514663 — intervention group
Group type: EXPERIMENTAL
Intervention: iTRAQ proteome analyses of bronchoalveolar lavage (BAL) cells from female COPD patients
Number of subjects: 43
Study 29514663 — intervention group
Group type: COMPARATOR
Intervention: iTRAQ proteome analyses of bronchoalveolar lavage (BAL) cells from smokers with normal lung function
Number of subjects: 43
Study 29514677 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) combined with Task-Oriented Balance Training (TOBT)
Number of subjects: 0
Study 29514677 — intervention group
Group type: COMPARATOR
Intervention: General Health Education (GHE) combined with Task-Oriented Balance Training (TOBT)
Number of subjects: 0
Study 29514690 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigorous exercise group
Number of subjects: 81
Study 29514690 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate exercise group
Number of subjects: 81
Study 29514690 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 81
Study 29514705 — intervention group
Group type: EXPERIMENTAL
Intervention: Auricular acupressure on active points (AA group)
Number of subjects: 112
Study 29514705 — intervention group
Group type: COMPARATOR
Intervention: Auricular acupressure on control points (SAA group)
Number of subjects: 112
Study 29514708 — intervention group
Group type: EXPERIMENTAL
Intervention: Regadenoson perfusion CMR
Number of subjects: 76
Study 29514773 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard care + one-way SMS reminder
Number of subjects: 300
Study 29514773 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 300
Study 29514815 — intervention group
Group type: EXPERIMENTAL
Intervention: Calgranulin-C (0.75 µg/g)
Number of subjects: 337
Study 29514815 — intervention group
Group type: EXPERIMENTAL
Intervention: Calprotectin (50 µg/g)
Number of subjects: 337
Study 29514815 — intervention group
Group type: EXPERIMENTAL
Intervention: Calprotectin (400 µg/g)
Number of subjects: 337
Study 29515036 — intervention group
Group type: EXPERIMENTAL
Intervention: RNA analysis
Number of subjects: 180
Study 29515036 — intervention group
Group type: EXPERIMENTAL
Intervention: DNA analysis
Number of subjects: 180
Study 29515036 — intervention group
Group type: EXPERIMENTAL
Intervention: Microbiota models (RNA and DNA)
Number of subjects: 180
Study 29515036 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole treatment for 14 days
Number of subjects: 180
Study 29515036 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall study
Number of subjects: 180
Study 29515114 — intervention group
Group type: EXPERIMENTAL
Intervention: Momelotinib (MMB; JAK1/2 inhibitor)
Number of subjects: 100
Study 29515350 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetitive peripheral magnetic stimulation (rPMS) of the neck and back muscles followed by repetitive transcranial magnetic stimulation (rTMS) of the left prefrontal and left temporoparietal cortex, 10 sessions.
Number of subjects: 41
Study 29515438 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation (tDCS)
Number of subjects: 0
Study 29515438 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo stimulation)
Number of subjects: 0
Study 29515514 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive abduction loading therapy with horizontal-plane viscous resistance
Number of subjects: 32
Study 29515514 — intervention group
Group type: COMPARATOR
Intervention: Progressive abduction loading therapy without horizontal-plane viscous resistance
Number of subjects: 32
Study 29516004 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress echocardiography
Number of subjects: 25
Study 29517074 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher-protein calorie-restricted diet
Number of subjects: 0
Study 29517074 — intervention group
Group type: COMPARATOR
Intervention: Calorie-restricted diet
Number of subjects: 0
Study 29517122 — intervention group
Group type: EXPERIMENTAL
Intervention: HR tertile 2 (77-94 b.p.m.)
Number of subjects: 0
Study 29517122 — intervention group
Group type: EXPERIMENTAL
Intervention: HR tertile 3 (>94 b.p.m.)
Number of subjects: 0
Study 29517122 — intervention group
Group type: EXPERIMENTAL
Intervention: Low SBP (<119 mmHg)
Number of subjects: 0
Study 29517567 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient e-learning program, brief advice, educational pamphlet, tobacco quitline referral, letter to the primary care physician, and pharmacotherapy
Number of subjects: 459